Keratoconus denials in California external review

In the California DMHC record, independent physician reviewers decided 35 published external-review cases involving keratoconusand overturned the plan’s denial in 88.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
35
2005–2022
Overturned
88.6%
31 denials reversed

Most-fought treatments for keratoconus

What insurers denied — and how those fights ended.
TreatmentDecisionsOverturned
Corneal Collagen Cross-linking18
83.3%

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
31
90.3%
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
4
75%
Typical time to a decision
21 days
Most land between 15 and 26 days

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for corneal collagen cross-linking procedure, on the left eye and prospective authorization and coverage, procedure code 0402T, on the right eye. The Health Plan has denied this request indicating that the procedures at issue were and are considered investigational for treatment of the enrollee’s keratoconus.Findings: There is support in the medical literature for the efficacy of the corneal crosslinking in this patient’s case. Cross-linking is a U.S. Food and Drug Administration (FDA) approved procedure for keratoconus and post refractive ectasia. The FDA approved this procedure in 2016. The primary purpose of crosslinking is to halt the progression of corneal thinning that occurs with conditions such as keratoconus.
Experimental/Investigational · 2018 · IMR EI18-27939
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for corneal collagen cross-linking procedure for treatment of the enrollee’s bilateral keratoconus. Findings: The 3 physician reviewers found that there is support in the medical literature for the superior efficacy of the services at issue in this patient’s case. Based on the patient’s vision loss and previous treatment with glasses and contacts, the cross-linking was the most appropriate and effective treatment available. There is a large body of available literature in support of corneal collagen cross-linking for treatment of this patient. The evidence shows corneal collagen cross-linking as a safe and effective procedure for stabilizing corneal ectasia and potentially delaying or preventing the need for full thickness corneal transplant.
Experimental/Investigational · 2018 · IMR EI18-27442

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for corneal collagen crosslinking procedure. The records provided for review document that this patient has a diagnosis of keratoconus. Thus, corneal crosslinking may be beneficial for treatment of keratoconus. Per the recommendations in the medical literature, a patient should have documentation of progression along with corneal scans and corneal thickness measurements prior to undergoing corneal crosslinking. Although this patient may be a candidate for corneal crosslinking, there is a lack of report that the patient has undergone a thorough evaluation by a provider with expertise and subspecialty training in corneal diseases to document progression via measurement and scans and measure the corneal thickness.
Medical Necessity · 2022 · IMR MN22-37750
A 40-year-old female enrollee has requested reimbursement for the bilateral ophthalmic dx image anterior tomography (anterior segment optical coherence tomography) for evaluation of the enrollee’s keratoconus. Findings: Three physician reviewers found that the patient was diagnosed with keratoconus by her in-network ophthalmologist. She was subsequently seen by an out-of-network ophthalmologist for additional consultation. Anterior optical coherence topography was provided as one of the services by the consultant. The patient’s best corrected visual acuity was 20/30+ in the right eye and 20/20 in the left eye. There is no indication in the medical record of spectacle correction or contact lens use. There is no mention of intolerance to contact lenses, corneal edema, or scarring.
Experimental/Investigational · 2012 · IMR EI12-14208

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving keratoconus, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for keratoconus? Use the California record to prepare.

Explain my denial — freeStart my appeal · $39